Tharimmune Board Changes and Officer Compensation

Ticker: CNTN · Form: 8-K · Filed: May 9, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateMay 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: director-departure, officer-compensation, governance

TL;DR

Tharimmune director resigns, exec comp details released.

AI Summary

Tharimmune, Inc. announced on May 9, 2025, a change in its board of directors. Specifically, Dr. Jonathan M. Roth, a director, has resigned. The company also reported on compensatory arrangements for its officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to understanding executive incentives.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes and compensation details, which are standard disclosures and do not indicate immediate significant risk.

Key Players & Entities

FAQ

Who has resigned from the Tharimmune, Inc. board of directors?

Dr. Jonathan M. Roth has resigned from the board of directors of Tharimmune, Inc.

What is the exact date of this filing?

The exact date of this filing is May 9, 2025.

What is the principal executive office address for Tharimmune, Inc.?

The principal executive office address is 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.

What is the Commission File Number for Tharimmune, Inc.?

The Commission File Number for Tharimmune, Inc. is 001-41210.

What are the main items reported in this 8-K filing?

This 8-K filing reports on the departure of a director, election of directors, appointment of officers, and compensatory arrangements of certain officers.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 by Dr. Jonathan M. Roth regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing